|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All IPs and associated SCCs were negative for p16 and hrHPV. lrHPV RNA was detected in 5/42 (12%) cases, including 3/5 (60%) with associated SCC (P=0.009).
|
31743131 |
2020 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HPV 16 and/or 18 were detected in 156 (80%) tumors. p16 was positive in 186 (96%) carcinomas, but eight tumors (4%) were negative for p16 (seven squamous cell carcinomas, one adenocarcinoma); 5/8 caused by HPV 16 and/or 18.
|
31492932 |
2020 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina.
|
30561092 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study investigated the immunohistochemical expression of retinoblastoma (RB) protein and p16 protein in 10 neuroendocrine carcinomas (NECs), in comparison to two mixed-type NECs; 28 squamous cell carcinomas (SCCs), and 12 carcinosarcomas (CSs) from patients with esophageal cancer.
|
30952735 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical relevance and significance of programmed death-ligand 1 expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma.
|
31190998 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All SCCs showed diffuse and intense p16 expression consistent with the presence of HPV.
|
29406447 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Samples from 100 OPSCC patients were analyzed using polymerase chain reaction (PCR) and p16 immunohistochemistry.
|
30594962 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to evaluate PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in squamous cell carcinoma (SCC) associated with emphysema/COPD.
|
31481045 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88).
|
31157548 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of this study demonstrate that Sec62/Ki67 and p16 Ki67 dual-staining cytology could be a promising adjunctive diagnostic tool for VIN and squamous cell carcinoma, in addition to standard histology.
|
30607586 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Comparison of P16 expression in OSCC tumors with different degrees of promoter methylation further suggest the relationship of methylation rate and down-regulation of P16 expression.
|
30511108 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The pathology databases were searched for all neck-mass FNAs diagnosed as squamous cell carcinoma from January 2010 to March 2019. p16 ICC was performed on cytology smears, and the percentage and intensity of p16-positive cells were assessed.
|
31246356 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the clinical samples of HNSCC, high expression of TrkA and panTrk were more associated with oropharyngeal and p16 positive squamous cell carcinoma (SCC).
|
30360033 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Histological and immunochemical analysis revealed the presence of a dual architectural pattern squamous cell carcinoma with a p16 negative and a p16 positive component.
|
30552721 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Squamous lesions were screened with immunohistochemical markers p16 and Ki-67 to compare expression in conjunctival papillomas (n = 21) to papillomas with high-grade dysplasia, SCC in situ, and invasive SCC (n = 40).
|
29533279 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated SOX2 immunohistochemical expression in normal cervix, low-grade squamous intraepithelial lesion (LSIL) (mild squamous dysplasia), high-grade squamous intraepithelial lesion (HSIL) (moderate and severe dysplasia) and SCC of the cervix in comparison with p16 and Ki-67.
|
27490766 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We retrospectively included 50 histologically confirmed p16 positive oropharyngeal squamous cell carcinomas (p16 positive immunostaining was defined by a strong staining in 70% or more of tumor cells).
|
29925856 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To evaluate the impact of HPV16 load (VL-the number of virus genome copies per cell) and P16 expression on prognosis of patients with squamous cell carcinomas (SCCs) of head and neck (HN).
|
29043437 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cancer stage and pack-years, but not p16 or HPV, are relevant for survival in hypopharyngeal and laryngeal squamous cell carcinomas.
|
29744637 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specimens from 1470 OPSCC patients collected from 2000 to 2016 were analyzed using the status of HPV by polymerase chain reaction (PCR) and p16 immunohistochemistry.
|
30310820 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, using 348 head and neck SCCs (126 OP SCCs and 222 non-OP SCCs), we evaluated diagnostic performances of different HPV tests in OP and non-OP SCCs: polymerase chain reaction, p16 immunostaining, in situ hybridization targeting DNA (DNA-CISH) and RNA (RNA-CISH), combined p16 + DNA-CISH, and combined p16 + RNA-CISH.
|
29684499 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, p16 expression was very weak in the normal and psoriasis groups compared with that in the SCC group.
|
29115643 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to evaluate the association of HPV and HIV status, p16 expression level and TP53 mutations with the absence of residual tumors (local response) in Squamous Cell Carcinoma (SCC) of the anal canal after chemoradiotherapy.
|
29466950 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As such, positive p16 immunohistochemistry cannot be used as supportive evidence for the diagnosis of squamous cell carcinoma as strong and diffuse p16 expression may also occur in follicular dendritic cell sarcoma.
|
28554574 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with thymic squamous cell carcinomas lacking p16 expression were younger (p = 0.006).
|
28179162 |
2017 |